| Literature DB >> 33587590 |
Zinan Zhang1, Dominic Ortega2, Anthony Rush3, Lauren R Blankenship2, Zi Jun Cheng2, Rebecca E Moore2, Minh L N Tran2, Lucero G Sandoval2, Kareem Aboulhosn2, Seiichiro Watanabe2, Kendra S Cortez2, David H Perlman4, Martin F Semmelhack1, Laura C Miller Conrad2.
Abstract
Infections with Pseudomonas aeruginosa are a looming threat to public health. New treatment strategies are needed to combat this pathogen, for example, by blocking the production of virulence factors like pyocyanin. A photoaffinity analogue of an antipyocyanin compound was developed to interrogate the inhibitor's molecular mechanism of action. While we sought to develop antivirulence inhibitors, the proteomics results suggested that the compounds had antibiotic adjuvant activity. Unexpectedly, we found that these compounds amplify the bactericidal activity of colistin, a well-characterized antibiotic, suggesting they may represent a first-in-class antibiotic adjuvant therapy. Analogues have the potential not only to widen the therapeutic index of cationic antimicrobial peptides like colistin, but also to be effective against colistin-resistant strains, strengthening our arsenal to combat P. aeruginosa infections.Entities:
Keywords: ArnA; PA14_30820; Pseudomonas aeruginosa; adjuvant; colistin
Mesh:
Substances:
Year: 2021 PMID: 33587590 PMCID: PMC8325921 DOI: 10.1021/acsinfecdis.0c00160
Source DB: PubMed Journal: ACS Infect Dis ISSN: 2373-8227 Impact factor: 5.084